Jia W - Search Results

1

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.

Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Ren Z, et al. Among authors: jia w. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143971 Clinical Trial.

2

Can hepatocellular carcinoma be treated by Yondelis through targeting both tumor cells and tumor-associated macrophages?

Zhang CH, Xu GL, Jia WD, Ge YS, Wang W. Zhang CH, et al. Among authors: jia wd. Hepatogastroenterology. 2010 Jan-Feb;57(97):114-6. Hepatogastroenterology. 2010. PMID: 20422884 Review.

3

Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.

Jia WD, Zhang CH, Xu GL, Ge YS, Wang W. Jia WD, et al. Hepatogastroenterology. 2010 Mar-Apr;57(98):292-9. Hepatogastroenterology. 2010. PMID: 20583430 Review.

4

Extracellular matrix protein 1, a novel prognostic factor, is associated with metastatic potential of hepatocellular carcinoma.

Chen H, Jia WD, Li JS, Wang W, Xu GL, Ma JL, Ren WH, Ge YS, Yu JH, Liu WB, Zhang CH, Wang YC. Chen H, et al. Among authors: jia wd. Med Oncol. 2011 Dec;28 Suppl 1:S318-25. doi: 10.1007/s12032-010-9763-1. Epub 2010 Dec 3. Med Oncol. 2011. PMID: 21128013

5

[Expression of estrogen receptor α in hepatitis B-related hepatocellular carcinoma and its clinical significance].

Han SJ, Xu GL, Jia WD, Wang YC, Li JS, Ma JL, Ren WH, Ge YS, Liu WB, Zhang CH, Wang W. Han SJ, et al. Among authors: jia wd. Zhonghua Wai Ke Za Zhi. 2010 Dec 15;48(24):1875-80. Zhonghua Wai Ke Za Zhi. 2010. PMID: 21211272 Chinese.

6

Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis.

Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, Ren WH. Zhang CH, et al. Int J Cancer. 2012 Jun 1;130(11):2685-92. doi: 10.1002/ijc.26301. Epub 2011 Sep 14. Int J Cancer. 2012. PMID: 21780114

7

High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma.

Lv Y, Wang W, Jia WD, Sun QK, Li JS, Ma JL, Liu WB, Zhou HC, Ge YS, Yu JH, Xia HH, Xu GL. Lv Y, et al. Among authors: jia wd. Med Oncol. 2013 Mar;30(1):385. doi: 10.1007/s12032-012-0385-7. Epub 2012 Dec 30. Med Oncol. 2013. PMID: 23275141

8

The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma.

Pan JJ, Ge YS, Xu GL, Jia WD, Liu WF, Li JS, Liu WB. Pan JJ, et al. J Cancer Res Clin Oncol. 2013 Jun;139(6):1043-54. doi: 10.1007/s00432-013-1415-3. Epub 2013 Mar 23. J Cancer Res Clin Oncol. 2013. PMID: 23525579

9

Overexpression of Mortalin in hepatocellular carcinoma and its relationship with angiogenesis and epithelial to mesenchymal transition.

Chen J, Liu WB, Jia WD, Xu GL, Ma JL, Huang M, Deng YR, Li JS. Chen J, et al. Int J Oncol. 2014 Jan;44(1):247-55. doi: 10.3892/ijo.2013.2161. Epub 2013 Nov 1. Int J Oncol. 2014. PMID: 24190572

10

Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma.

Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu JH, Xu GL, Ma JL, Zhong W, Jia WD. Sun QK, et al. Among authors: jia wd. Med Oncol. 2014 Jan;31(1):786. doi: 10.1007/s12032-013-0786-2. Epub 2013 Dec 3. Med Oncol. 2014. PMID: 24297309

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,564 results

Search Page

Filters